Literature DB >> 19417716

Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.

Melanie Mueller1, Erin A Kolbrich, Frank T Peters, Hans H Maurer, Una D McCann, Marilyn A Huestis, George A Ricaurte.   

Abstract

The present study compared the disposition and metabolism of the recreational drug (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in squirrel monkeys and humans because the squirrel monkey has been extensively studied for MDMA neurotoxicity. A newly developed liquid chromatography-mass spectrometric procedure for simultaneous measurement of MDMA, 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine, and 3,4-methylenedioxyamphetamine was employed. In both humans and squirrel monkeys, a within-subject design permitted testing of different doses in the same subjects. Humans and squirrel monkeys were found to metabolize MDMA in similar, but not identical, pathways and proportions. In particular, amounts of 3,4-dihydroxymethamphetamine (after conjugate cleavage) and 3,4-methylenedioxyamphetamine were similar in the 2 species, but formation of 4-hydroxy-3-methoxymethamphetamine was greater in squirrel monkeys than in humans. Both species demonstrated nonlinear MDMA pharmacokinetics at comparable plasma MDMA concentrations (125-150 ng/mL and above). The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours). In both species, there was substantial individual variability. These results suggest that the squirrel monkey may be a useful model for predicting outcomes of MDMA exposure in humans, although this will also depend on the degree to which MDMA pharmacodynamics in the squirrel monkey parallels that in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417716      PMCID: PMC3159867          DOI: 10.1097/FTD.0b013e3181a4f6c2

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  17 in total

1.  Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.

Authors:  Annis Mechan; Jie Yuan; George Hatzidimitriou; Rodney J Irvine; Una D McCann; George A Ricaurte
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

2.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors:  R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 3.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

Review 4.  The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.

Authors:  Terrence J Monks; Douglas C Jones; Fengju Bai; Serrine S Lau
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

Review 5.  Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

Authors:  Rafael de la Torre; Magí Farré; Pere N Roset; Neus Pizarro; Sergio Abanades; Mireia Segura; Jordi Segura; Jordi Camí
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

6.  Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage.

Authors:  Melanie Mueller; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Forensic Sci Int       Date:  2009-01-07       Impact factor: 2.395

7.  Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.

Authors:  Yamini Ramamoorthy; Ai-ming Yu; Nina Suh; Robert L Haining; Rachel F Tyndale; Edward M Sellers
Journal:  Biochem Pharmacol       Date:  2002-06-15       Impact factor: 5.858

Review 8.  3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans.

Authors:  T D Steele; U D McCann; G A Ricaurte
Journal:  Addiction       Date:  1994-05       Impact factor: 6.526

9.  Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion.

Authors:  T Chu; Y Kumagai; E W DiStefano; A K Cho
Journal:  Biochem Pharmacol       Date:  1996-03-22       Impact factor: 5.858

10.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).

Authors:  G T Tucker; M S Lennard; S W Ellis; H F Woods; A K Cho; L Y Lin; A Hiratsuka; D A Schmitz; T Y Chu
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

View more
  7 in total

1.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

2.  Weekend Ecstasy use disrupts memory in rats.

Authors:  Leah M McAleer; Timothy Schallert; Christine L Duvauchelle
Journal:  Neurosci Lett       Date:  2013-05-22       Impact factor: 3.046

3.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

4.  Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

5.  A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Matthew G Kirkpatrick; Erik W Gunderson; Audrey Y Perez; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2011-06-30       Impact factor: 4.530

6.  Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.

Authors:  Michael H Baumann; Dorota Zolkowska; Insook Kim; Karl B Scheidweiler; Richard B Rothman; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2009-08-13       Impact factor: 3.922

7.  Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons.

Authors:  Amy K Goodwin; Melanie Mueller; Courtney D Shell; George A Ricaurte; Nancy A Ator
Journal:  J Pharmacol Exp Ther       Date:  2013-03-20       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.